WHAT ARE THE ISSUES?
On Aug. 30, 2017, the Food and Drug Administration (FDA) approved the first gene therapy product to launch in the U.S. Novartis’ drug—brand name Kymriah—is now out of the clinic and available to patients. Eye-watering price aside, it has been hailed as a landmark event in the history of the U.S. pharma industry.
The clinical trials le…
Keep reading with a 7-day free trial
Subscribe to INSIDE PHARMA to keep reading this post and get 7 days of free access to the full post archives.